Filter by

Format

All

All
Videos
Clinical Studies

Sort by

Newest

Newest
Oldest

Metabolic

Jardiance

/sa/metabolic/jardiance/crm/t2d-progressive-disease-requires-holistic-approach

1:12

T2D is a Progressive Disease that requires a holistic approach

/sa/metabolic/jardiance/crm/global-clinical-guidelines-recommendation-preferential-use-sglt2-inhibitors-patients-t2d

2:52

Global Clinical Guidelines Recommendation for the Preferential Use of SGLT2 inhibitors in Patients with T2D and CKD

/sa/metabolic/jardiance/crm/kdigo-guidelines-2022-update

4:27

KDIGO Guidelines 2022 Update

/sa/metabolic/jardiance/crm/empa-reg-trial-kidney-outcomes-t2d-patients

5:22

EMPA REG Trial Kidney Outcomes for T2D Patients

/sa/metabolic/jardiance/crm/empa-reg-trial-outcomes-t2d-and-cv-disease-patients

3:35

EMPA-REG Trial Outcomes for T2D and CV Disease Patients

/sa/metabolic/jardiance/crm/ada-2022-guidelines-t2d-management-hf-ckd-patients

0:41

ADA 2022 Guidelines for T2D Management of HF & CKD patients

/sa/metabolic/jardiance/crm/sglt2i-and-cv-outcomes-patients-cv-risk

02:38

SGLT2i and CV Outcomes for Patients with CV Risk

/sa/metabolism/jardiance/safety/jardiance-can-now-be-used-down-egfr-30-mlmin173-m2

JARDIANCE can now be used down to an eGFR of 30 mL/min/1.73 m2

Respiratory

OFEV

/sa/respiratory/ofev/safety-and-tolerability/cv-safety-ofev-test-need-to-delete-not-in-seo

CV safety of OFEV